Oral
T-DXd
ASCO 2026 | May 29 - June 2, 2026
A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P)
This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Oral
T-DXd
JSMO 2026 | March 26-28, 2026
A health-related quality-of-life analysis from ERICA study (WJOG14320B)
Poster
T-DXd
ESMO Breast 2026 | May 6-8, 2026
A multicenter, retrospective study to determine the prevalence of HER2-low & associated outcomes in patients previously identified with HER2 negative locally advanced (LA) or metastatic breast cancer (mBC) who progressed on systemic anticancer therapy: Interim analysis of iRetroBC-HER2L study
Mini-Oral
T-DXd
SABCS 2025 | December 9 - 12, 2025
Additional efficacy and safety from the DESTINY-Breast05 study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary early breast cancer with residual invasive disease after neoadjuvant therapy
Oral
T-DXd
JBCS 2025 | July 10-12, 2025
AI-based analyses of trastuzumab deruxtecan-related interstitial lung disease/pneumonitis: TILD-A
Poster
T-DXd
AACR 2026 | April 17-22, 2026
Comparison of digital and computational algorithms for quantifying human epidermal growth factor receptor 2 (HER2) protein expression in metastatic breast cancer (mBC) from clinical samples
Oral
Dato-DXd
ESMO 2025 | October 17-21, 2025
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as
first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer: Results from arms 7 and 8 of the phase 1b/2 BEGONIA study
Poster
T-DXd
SABCS 2025 | December 9 - 12, 2025
DESTINY-Breast Respond HER2-low Europe:
Description of first enrolled patients in the
non-interventional study of T-DXd in HER2-low
metastatic breast cancer
Poster
T-DXd
Miami Breast 2026 | March 5-8, 2026
DESTINY-Breast06 post hoc analysis by physician’s choice of chemotherapy: Efficacy and safety of trastuzumab deruxtecan versus physician’s choice of chemotherapy in hormone receptor–positive, HER2-low or -ultralow metastatic breast cancer
Mini-Oral
T-DXd
SABCS 2025 | December 9 - 12, 2025
DESTINY-Breast11 safety: Neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer